Donepezil delays progression to AD in MCI subjects with depressive symptoms.

ABSTRACT:

Objective

To determine whether the presence of depression predicts higher rate of progression to Alzheimer disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and whether donepezil treatment beneficially affect this relationship.

Methods

The study sample was composed of 756 participants with aMCI from the 3-year, double-blind, placebo-controlled Alzheimer's Disease Cooperative Study drug trial of donepezil and vitamin E. Beck Depression Inventory (BDI) was used to assess depressive symptoms at baseline and participants were followed either to the end of study or to the primary endpoint of progression to probable or possible AD.

Results

Cox proportional hazards regression, adjusted for age at baseline, gender, apolipoprotein genotype, and NYU paragr

SUBMITTER: Lu PH 

PROVIDER: S-EPMC2697965 | biostudies-literature | 2009 Jun

REPOSITORIES: biostudies-literature